查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571600

癌症登记软体市场规模、份额、趋势分析报告：按软体、按部署模型、按组件、按最终用途、按地区、细分市场预测，2024-2030 年

Cancer Registry Software Market Size, Share & Trends Analysis Report By Software (Standalone), By Deployment model (On-premise), By Component (Commercial), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

癌症登记软体市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计2030年全球癌症登记软体市场规模将达到1.724亿美元，2024年至2030年复合年增长率为12.7%。

癌症发生率的增加预计将推动预测期内的成长。癌症目前是全球第二大死因，根据世界卫生组织的数据，约 70% 的死亡发生在低收入和中等收入国家。

此外，已开发国家电子健康记录(EHR) 的采用率不断上升，以及对上市后监测的癌症登记的需求不断增长，预计将在未来几年进一步推动对癌症登记软体的需求。市场公司不断致力于软体更新，以最大限度地降低安全风险并提供高效的软体，从而提高市场认知度和采用率。例如，2018年4月，Elekta投资了PalabraApps LLC，以改善其MOSAIQ肿瘤资讯系统软体。

大型製药企业进行的临床试验数量不断增加，预计将在预测期内推动市场发展。癌症登记资料可以帮助追踪患者进行临床试验。此外，该软体还可用于识别某些类型癌症的受影响区域。由于对内部员工的需求减少、成本效益提高以及资源管理高效，大型製药公司越来越青睐癌症登记软体，这将进一步推动其扩张。

癌症登记软体市场报告亮点

  • 独立软体占据市场主导地位，到 2023 年将占 80.8% 的份额。
  • 从部署模式来看，本地部署模式将占据市场主导地位，到 2023 年将占据 59.8% 的份额。
  • 从组成部分来看，商业细分市场占据主导地位，2023 年将占据 75.0% 的份额。
  • 政府和第三方部门主导市场，2023年占27.2%的份额。
  • 2023年，北美癌症登记软体市占率最大，为44.0%。
  • 预计亚太地区在预测期内将以 14.8% 的复合年增长率增长最快。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章癌症登记软体市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 癌症登记软体市场分析工具
    • 波特的分析
    • PESTEL分析

第四章癌症登记软体市场：软体估计和趋势分析

  • 细分仪表板
  • 癌症登记软体市场：2023 年和 2030 年软体变化分析
  • 独立的
  • 融合的

第五章癌症登记软体市场：按部署模型进行估计和趋势分析

  • 细分仪表板
  • 癌症登记软体市场：2023 年和 2030 年按部署模型分類的变化分析
  • 本地
  • 云端基础

第六章癌症登记软体市场：按组成部分的估计和趋势分析

  • 细分仪表板
  • 癌症登记软体市场：2023 年和 2030 年按组件分類的变化分析
  • 商业的
  • 公共

第七章癌症登记软体市场：最终用途的估计和趋势分析

  • 细分仪表板
  • 癌症登记软体市场：2023 年和 2030 年最终用途的变化分析
  • 政府和第三方
  • 私人保险公司
  • 医院和医疗实践
  • 製药生物技术和医疗设备公司
  • 研究所

第八章癌症登记软体市场：按地区估计和趋势分析

  • 癌症登记软体市场占有率：按地区划分，2023 年和 2030 年
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Elekta
    • Oracle
    • ONCO, Inc.
    • IBM
    • MCKESSON CORPORATION
    • Conduent, Inc.
    • Ordinate Corporation
    • Volpara Health Limited
    • Health Catalyst
    • Rocky Mountain Cancer Data Systems（RMCDS）（University of Utah Health）
简介目录
Product Code: GVR-3-68038-753-7

Cancer Registry Software Market Growth & Trends:

The global cancer registry software market size is expected to reach USD 172.4 million by 2030, registering a CAGR of 12.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing incidence of cancer is expected to aid growth over the forecast period. Currently, cancer is the second leading cause of death globally, and according to WHO, around 70% of the deaths occur in low- and middle-income countries.

Moreover, rising adoption of Electronic Health Records (EHRs) in developed countries and increasing need for cancer registries for post-marketing surveillance are among the factors further anticipated to boost the demand for cancer registry software in the coming years. Market players are constantly involved in software updation in an attempt to minimize security risks and provide efficient software, thereby increasing market visibility and adoption. For instance, in April 2018, Elekta invested in PalabraApps LLC to improve its MOSAIQ Oncology Information System software.

Increasing number of clinical trials being conducted by major pharmaceutical and biotechnological companies is expected to drive the market over the forecast period. Cancer registry data helps in tracking patients for clinical trials. Moreover, the affected locations for any specific type of cancer can be identified by using this software. Major pharmaceutical companies are increasingly preferring cancer registry software owing to less requirement of internal staff, increased cost-effectiveness, and efficient management of resources, which is further widening the scope for growth.

Cancer Registry Software Market Report Highlights:

  • Standalone software dominated the market and accounted for a share of 80.8% in 2023 attributed to its advanced features and easy-to-use tools.
  • On the basis of deployment model, on-premise model segment dominated the market and accounted for a share of 59.8% in 2023.
  • On the basis of components, the commercial segment dominated the market and accounted for a share of 75.0% in 2023 owing to its advantage of data safety as compared to the public database.
  • The government & third-party segment dominated the market and accounted for a share of 27.2% in 2023.
  • North America cancer registry software market accounted for the largest revenue share of 44.0% in 2023, owing to the presence of developed infrastructure.
  • The Asia Pacific is expected to grow at the fastest CAGR of 14.8% over the forecast period, owing to increasing government initiatives in this region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Cancer Registry Software Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Cancer Registry Software Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Cancer Registry Software Market: Software Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Cancer Registry Software Market: Software Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Standalone
    • 4.3.1. Standalone Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Integrated
    • 4.4.1. Integrated Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cancer Registry Software Market: Deployment Model Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Cancer Registry Software Market: Deployment Model Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. On-premise
    • 5.3.1. On-premise Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Cloud Based
    • 5.4.1. Cloud Based Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cancer Registry Software Market: Component Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Cancer Registry Software Market: Component Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Commercial
    • 6.3.1. Commercial Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Public
    • 6.4.1. Public Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Cancer Registry Software Market: End-use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Cancer Registry Software Market: End-use Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Government & Third Party
    • 7.3.1. Government & Third-Party Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Private Payers
    • 7.4.1. Private Payers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Hospital & Medical Practice
    • 7.5.1. Hospital & Medical Practice Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Pharma Biotech & Medical Device Companies
    • 7.6.1. Pharma Biotech & Medical Device Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Research Institutes
    • 7.7.1. Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Cancer Registry Software Market: Regional Estimates & Trend Analysis

  • 8.1. Cancer Registry Software Market Share, By Region, 2023 & 2030, USD Million
  • 8.2. North America
    • 8.2.1. North America Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Canada Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Germany Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. France Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Italy Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Spain Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Norway Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. China Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. India Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Australia Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. South Korea
      • 8.4.6.1. South Korea Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Thailand Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. UAE Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. Elekta
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. Oracle
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. ONCO, Inc.
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. IBM
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. MCKESSON CORPORATION
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Conduent, Inc.
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Recent Developments/ Strategic Initiatives
    • 9.4.7. Ordinate Corporation
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/ Strategic Initiatives
    • 9.4.8. Volpara Health Limited
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Health Catalyst
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. Rocky Mountain Cancer Data Systems (RMCDS) (University of Utah Health)
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/ Strategic Initiatives